Genzyme: Engineering the Market for Orphan Drugs Harvard Case Solution & Analysis

Genzyme has made money with external technology in children's drug market is generally considered too small to be attractive to other pharmaceutical companies. Now the competition is entering these markets, placing the business model Genzyme under new pressure. "Hide
by Henry W. Chesbrough, Clarissa Ceruti Source: Harvard Business School 20 pages. Publication Date: March 26, 2002. Prod. #: 602147-PDF-ENG

Genzyme: Engineering the Market for Orphan Drugs Case Solution Other Similar Case Solutions like

Genzyme: Engineering the Market for Orphan Drugs

Share This